Grace Therapeutics, Inc. (GRCE)
1.87
+0.09
(+5.06%)
USD |
NASDAQ |
Nov 06, 10:23
Grace Therapeutics EPS Diluted (Quarterly) : -0.9143 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.9143 |
| March 31, 2026 | -0.0735 |
| December 31, 2025 | -0.1367 |
| September 30, 2025 | -0.0589 |
| June 30, 2025 | -0.2111 |
| March 31, 2025 | 0.0464 |
| December 31, 2024 | -0.3611 |
| September 30, 2024 | -0.2983 |
| June 30, 2024 | -0.2395 |
| March 31, 2024 | -0.3368 |
| December 31, 2023 | -0.2078 |
| September 30, 2023 | -0.4334 |
| June 30, 2023 | -0.541 |
| March 31, 2023 | -3.912 |
| December 31, 2022 | -0.523 |
| September 30, 2022 | -0.6638 |
| June 30, 2022 | -0.6124 |
| March 31, 2022 | -0.5289 |
| December 31, 2021 | -0.5118 |
| September 30, 2021 | 0.1795 |
| June 30, 2021 | -0.7181 |
| March 31, 2021 | -1.44 |
| December 31, 2020 | -1.399 |
| September 30, 2020 | -3.101 |
| June 30, 2020 | -2.470 |
| Date | Value |
|---|---|
| March 31, 2020 | 0.00 |
| December 31, 2019 | -6.707 |
| September 30, 2019 | -12.22 |
| June 30, 2019 | -5.400 |
| March 31, 2019 | -7.767 |
| December 31, 2018 | -2.366 |
| September 30, 2018 | -22.77 |
| June 30, 2018 | -8.550 |
| March 31, 2018 | -12.14 |
| December 31, 2017 | -15.10 |
| September 30, 2017 | -11.87 |
| June 30, 2017 | -6.783 |
| February 28, 2017 | 0.00 |
| November 30, 2016 | -7.965 |
| August 31, 2016 | -8.138 |
| May 31, 2016 | -10.71 |
| February 29, 2016 | -6.213 |
| November 30, 2015 | -7.635 |
| August 31, 2015 | -3.755 |
| May 31, 2015 | -3.876 |
| February 28, 2015 | -7.979 |
| November 30, 2014 | 12.88 |
| August 31, 2014 | -13.30 |
| May 31, 2014 | 4.365 |
| February 28, 2014 | -8.827 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ANI Pharmaceuticals, Inc. | 1.052 |
| Corcept Therapeutics, Inc. | 1.010 |
| Veru, Inc. | -0.3032 |
| Johnson & Johnson | 0.0858 |
| Eli Lilly & Co. | 7.221 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -15.79M |
| Total Expenses (Quarterly) | 15.79M |
| Enterprise Value | 15.21M |
| Earnings Yield | -63.28% |
| Normalized Earnings Yield | -37.22 |